CVRx Investors Face Jan. 8 Deadline to Seek Lead Plaintiff Role

Investors who bought CVRx common stock from July 25, 2023, through Aug. 6, 2026, have until Jan. 8, 2027, to seek appointment as lead plaintiff in a filed securities lawsuit. Rosen Law Firm announced the deadline Nov. 12.

A lead plaintiff represents other people in the proposed class and directs the litigation. The court has not certified a class, and investors do not have to seek the lead role to remain eligible for any potential recovery.

Rosen Law Firm said the complaint alleges defendants made materially false and misleading statements about CVRx’s revenue growth, sales practices, regulatory compliance, reimbursement strategy and sales-force productivity. It also alleges the company generated some revenue through improper marketing of its Barostim device, kickbacks and false information submitted to government health insurance programs.

The complaint further alleges that sales-force turnover stayed elevated and productivity lagged because many representatives needed more training and time to become productive. Investors seeking appointment as lead plaintiff must ask the court by Jan. 8, 2027.